The AACC will review Holmes' slides before they are presented, Pollen said, but it won't investigate the validity of their content.
Holmes will answer questions from the audience -- made up of laboratory medicine experts and academics -- at the end of her presentation. Pollen said those in attendance will include people who work on microfluidics and will be able to "speak to what [Theranos'] technology does and how valid it is."
Theranos has never presented data or published research in a scientific journal that would demonstrate the effectiveness of its proprietary blood-analysis technology, which the company calls "Edison."
Theranos, a private company, came to prominence and achieved a valuation as high as $10 billion by claiming it could perform a variety of tests using only the small amount of blood obtained from a single finger prick, collected in small capsules called "nanotainers."
But the FDA has only approved that technology for one test, for herpes, and more recently an investigation by The Wall Street Journal and a scathing government report on Theranos' California lab have cast serious doubt over whether the company's claims have any merit. The Centers for Medicare & Medicaid Services, which issued the report, is now considering whether to levy harsh penalties on both Theranos and Holmes.
In February, The Financial Times reported that pharmacy chain Walgreens was looking for a way out of its partnership with the startup.
Just today, on NBC's "Today" show, Holmes broke her silence on the government's contention that problems at its lab have put patients in serious jeopardy, saying she was "devastated that we did not catch and fix these issues faster."
When asked if the company would survive its current travails, she said, "Absolutely."